Gritstone bio Inc. (GRTS) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/04/22
Gritstone Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/03/22
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/26/22
Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious DiseasesGlobeNewsWire • 10/25/22
Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022GlobeNewsWire • 09/12/22
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid TumorsGlobeNewsWire • 08/15/22
Gritstone bio Inc. (GRTS) CEO Andrew Allen on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/05/22
Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022GlobeNewsWire • 07/21/22
Gritstone bio: Investing In A Premium mRNA Technology At A Discounted ValuationSeeking Alpha • 06/14/22
Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature CommunicationsGlobeNewsWire • 06/10/22
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/06/22